Meta Agrees to $18 Billion Settlement, Tightens Teen Social Media Rules 
Honda, Nissan Eye Shared Vehicle Software Platform by 2029 
Trian Drops Wendy’s Take-Private Bid Plans, Shares Plunge 14% 
Nvidia Pauses AI Cloud Financing Deals Amid Antitrust Concerns 
Toyota Global Sales Fall as China Demand Slumps 
Itochu Offers $1.56 Billion to Privatize Dentsu Soken 
PayPal Shares Sink as $50 Billion Takeover Bid Collapses 
SK Biopharmaceuticals Secures Global Rights to Biohaven Epilepsy Drug Opakalim 
Nvidia Revenue Soars 106% as AI Demand Hits ‘Inflection Point’ 
SoftBank Eyes $20 Billion Bond Sale to Refinance OpenAI Loan 
Yindjibarndi Appeals Fortescue Mining Compensation Ruling 
OpenAI Data Center Chief Chris Malone Exits Ahead of Planned 2027 Listing 
The Realist’s Case: Lukas Kerrebijn of RD Dubai on the Narrative Dubai’s Agents Won’t Question 
Nvidia Reportedly Eyes $13 Billion Hugging Face Acquisition 
Amazon Secures 200 MW Wind Power Deals in Sweden 
Mercer International Stock Surges 45% on C$20 Million Canada Funding 
Add as a preferred source on Google
SEATTLE, April 09, 2018 -- NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced that the Company will release first quarter 2018 financial results after the close of trading on Tuesday, May 8, 2018. Company management will host a conference call beginning at 4:30pm ET to discuss those results and provide a business update.
Individuals interested in listening to the conference call may do so by dialing (888) 793-9492 for domestic callers, or (734) 385-2643 for international callers. Please reference Conference ID: 6188428. To listen to a live webcast, please visit the investor relations section of the company’s website at nanostring.com.
A replay of the call will be available beginning May 8, 2018 at 7:30pm ET through midnight on May 15, 2018. To access the replay, dial (855) 859-2056 or (404) 537-3406 and reference Conference ID: 6188428. The webcast will also be available on the Company’s website for one year following the completion of the call.
About NanoString Technologies, Inc.
NanoString Technologies provides life science tools for translational research and molecular diagnostic products. The company's nCounter Analysis System has been employed in life sciences research since it was first introduced in 2008 and has been cited in more than 1,900 peer-reviewed publications. The nCounter Analysis System offers a cost-effective way to easily profile the expression of hundreds of genes, proteins, miRNAs, or copy number variations, simultaneously with high sensitivity and precision, facilitating a wide variety of basic research and translational medicine applications, including biomarker discovery and validation. The company's technology is also being used in diagnostics. The Prosigna® Breast Cancer Prognostic Gene Signature Assay together with the nCounter Dx Analysis System is FDA 510(k) cleared for use as a prognostic indicator for distant recurrence of breast cancer. In addition, the company is collaborating with multiple biopharmaceutical companies in the development of companion diagnostic tests for various cancer therapies, helping to realize the promise of precision oncology. For more information, please visit www.nanostring.com.
Contact:
Doug Farrell
Vice President, Investor Relations & Corporate Communications
[email protected]
Phone: 206-602-1768
